Achieving durable glycaemic control to reduce the long-term
risk of diabetes-related morbidity and mortality remains a central therapeutic challenge in the management of patients with
type 2 diabetes. Drug therapy may fail, either initially or over
time [1], requiring treatment intensification [2].